Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

NCT04995523

Active Not RecruitingPhase 1, Phase 2

Sponsor: AstraZeneca

Conditions: Non-Small-Cell Lung Carcinoma

Interventions: AZD2936

Countries: United States, Australia, Belgium, Brazil, China, Denmark, France, Georgia

This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.

Eligibility overview

Sex: ALL

Age: 18 Years to 130 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Written informed consent
* Aged 18 or above
* Part A and Part B: Unresectable stage III or stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part C and Part D: Stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part E: Stage IV squamous NSCLC not amenable to curative surgery or radiation.
* Documented PD-L1 expression by PD-L1 IHC per local report.
* Part A and Part B: Confirmed progression during treatment with a CPI-including regimen.
* Part C and Part D: No prior I/O treatment for metastatic NSCLC.
* Part E: No prior treatment for metastatic NSCLC.
* ECOG performance status of 0 or 1 at enrolment.
* Life expectancy of ≥ 12 weeks at enrolment.
* Have at least 1 measurable lesion per RECIST v1.1.
* Adequate bone marrow, liver and kidney function

Exclusion Criteria:

* Sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusion
* Documented test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care (e.g. ROS1, NTRK fusions, BRAF, V600E mutation)
* Previous treatment with an anti-TIGIT therapy
* Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.
* Part A and Part B: Primary or secondary resistance after treatment with 2 or more regiments including a CPI.
* Part C and Part D: Any prior systemic treatment with an immune oncology agent (prior administration of immune-oncology agent for curative intent to treat other invasive malignancy is permitted).

Treatment with one previous systemic chemotherapy will be allowed.

* Part E: Any prior systemic treatment for metastatic NSCLC, including but not limited to chemotherapy, anti-PD-1, anti-PD-L1, anti-CTLA-4.
* Symptomatic central nervous system (CNS) metastasis.
* Thromboembolic event within 3 months prior to enrolment.
* Other invasive malignancy within 2 years prior to screening.
Locations (40)
  • Chicago, Illinois, United States
  • Rochester, Minnesota, United States
  • Fairfax, Virginia, United States
  • Melbourne, Australia
  • Anderlecht, Belgium
  • Leuven, Belgium
  • Florianópolis, Brazil
  • Natal, Brazil
  • Porto Alegre, Brazil
  • Rio de Janeiro, Brazil
  • São Paulo, Brazil
  • Chengdu, China
  • Chongqing, China
  • Copenhagen, Denmark
  • Dijon, France
  • Toulouse, France
  • Tbilisi, Georgia
  • Kashiwa, Japan
  • Niigata, Japan
  • Sendai, Japan
  • Tokyo, Japan
  • Kuala Lumpur, Malaysia
  • Kuching, Malaysia
  • Chisinau, Moldova
  • Groningen, Netherlands
  • Leiden, Netherlands
  • Utrecht, Netherlands
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • + 10 more on CT.gov